We conducted the first-in-human study of 18 F-fluoroethyl triazole [Tyr 3 ] octreotate ( 18 F-FET-βAG-TOCA) in patients with neuroendocrine tumors (NETs) to evaluate biodistribution, dosimetry, and safety. Despite advances in clinical imaging, detection and quantification of NET activity remains a challenge, with no universally accepted imaging standard. Methods: Nine patients were enrolled. Eight patients had sporadic NETs, and 1 had multiple endocrine neoplasia type 1 syndrome. Patients received 137-163 MBq (mean ± SD, 155.7 ± 8 MBq) of 18 F-FET-βAG-TOCA. Safety data were obtained during and 24 h after radioligand administration. Patients underwent detailed wholebody PET/CT multibed scanning over 4 h with sampling of venous bloods for radioactivity and radioactive metabolite quantification. Regions of interest were defined to derive individual and mean organ residence times; effective dose was calculated with OLINDA 1.1. Results: All patients tolerated 18 F-FET-βAG-TOCA with no adverse events. Over 60% parent radioligand was present in plasma at 60 min. High tumor (primary and metastases)-to-background contrast images were observed. Physiologic distribution was seen in the pituitary, salivary glands, thyroid, and spleen, with low background distribution in the liver, an organ in which metastases commonly occur. The organs receiving highest absorbed dose were the gallbladder, spleen, stomach, liver, kidneys, and bladder. The calculated effective dose over all subjects (mean ± SD) was 0.029 ± 0.004 mSv/MBq. Conclusion: The favorable safety, imaging, and dosimetric profile makes 18 F-FET-βAG-TOCA a promising candidate radioligand for staging and management of NETs. Clinical studies in an expanded cohort are ongoing to clinically qualify this agent.
Neur oendocrine tumors (NETs) are a heterogeneous group.
Once thought of as rare tumors, the incidence and prevalence has risen over the last 3 decades, with figures from the National Cancer Institute's Surveillance, Epidemiology and End Results Database showing a 520% increase, now surpassing other gastrointestinal tumors and sharing the same incidence rates as tumors of the cervix and multiple myeloma (1) . Gastroenteropancreatic NETs are the most common subtype, with the small bowel being the most frequent site (1, 2) .
Clinical presentation can vary and depends on the location of the tumor, presence of secretory products, and metastatic potential. Imaging is a pivotal part of the clinical workup when staging NET patients as well as aiding in treatment decisions and predicting response to therapy. Current anatomic imaging modalities, namely ultrasound, CT, MRI, and somatostatin receptor scintigraphy, fall short, with low sensitivity (82%-93%, 73%-83%, 89%-93%, and 89%, respectively) and operator dependence (ultrasound), thereby greatly underestimating the stage of disease (3, 4) . 68 Ga-DOTA-radiolabeled somatostatin analogs ( 68 Ga-labeled DOTATOC, DOTANOC, or DOTATATE) have been developed for use with PET; more recently, 64 Cu-DOTATATE has also been developed although the isotope has a branching ratio of 0.175 and a 12.7-h half-life. 68 Ga PET is far superior to somatostatin receptor scintigraphy in terms of resolution and sensitivity (5) (6) (7) . 18 F-somatostatin analogs represent a cyclotron-generated alternative to 68 Ga analogs. Thus, we developed a novel 18 F-click-labeled octreotate radioligand, 18 F-fluoroethyl triazole [Tyr 3 ] octreotate ( 18 F-FET-bAG-TOCA), for somatostatin receptor type 2 (SSTR-2) imaging (8, 9) . 18 F-FET-bAG-TOCA ( Fig. 1A) , synthesized using a versatile 2-step method to label [Tyr3] octreotate via copper catalyzed azide-alkyne cycloaddition reaction (also known as click chemistry), was shown to be superior to other 18 F-octreotate-labeled ligands and 68 Ga-DOTATATE in preclinical models, with good tumor uptake and low nonspecific liver uptake (8) .
We present the first-in-human biodistribution, dosimetry, and safety study of this radioligand in patients with NETs.
MATERIALS AND METHODS

Radiopharmaceutical Preparation
18 F-FET-bAG-TOCA was synthesized via the click reaction (9) . Briefly, 18 F-fluoride in a solution of oxygen-18-enriched water was transferred with a sweep of argon gas from the cyclotron target to the hot cell containing the automated module for radiochemistry. The 18 F-fluoride was then trapped on an ion exchange cartridge (Sep-Pak QMA-carbonate Light Cartridge; Waters); released into the FASTLab reaction vessel (Waters), using 1.5 mL of a solution containing Kryptofix K 222 and K 2 CO 3 ; and evaporated to dryness. A solution of 2-azidoethyl-p-toluenesulfonate (6 mL) in dry acetonitrile (1 mL) was added to the reaction vessel, and the solution was heated to 80°C for 15 min. The formed 18 F-fluoroethyl azide was then distilled at 120°C into a vial containing a solution of copper sulphate (3.25 mg) in water (25 mL) and a solution of bAG-TOCA (4 mg; obtained under contract from ABX [ABX Advanced Biochemical Compounds GmbH]) in N,N-dimethylformamide (50 mL). After distillation, 100 mL of a sodium ascorbate solution (56.7 mg in 2 mL of sodium acetate buffer) and 100 mL of a solution of bathophenanthroline disulfonic acid disodium salt trihydrate (192 mg) in 2 mL of water were added. The resulting mixture was mixed and allowed to react at room temperature for 5 min. The solution was then diluted with water and loaded onto semiprep high-performance liquid chromatography (HPLC) column (Jupiter Proteo [Phenomenex], 250 · 10 mm, 4 mm, 90 Å ) for purification. The semiprep HPLC column was eluted at a 3 mL/min flow with a premixed solution consisting of water/acetonitrile/ethanol/concentrated HCl, 740/250/10/1. The product fraction eluting at the retention time corresponding to 18 F-FET-bAG-TOCA was collected, diluted with 30 mL of ascorbic acid solution, and passed through a tC18 light Sep-Pak cartridge (Waters Corp.). After an initial Sep-Pak cartridge wash with sterile water, 18 F-FET-bAG-TOCA was eluted off the cartridge with ethanol, 0.9% saline for injection, and water for injection to produce 18 F-FET-bAG-TOCA formulated in 8 mL of maximum 12% (v/v) ethanol in 0.1% saline for injection. In the final step, the resulting formulation solution was filtered through a 0.2-mm sterile filter (Millex GV, Sterile, 0.22 mm; Millipore) into its final sterile container. The identity and purity (chemical and radiochemical purity) of the final product were determined by HPLC. Other quality control tests were performed according to European Pharmacopoeia guidelines.
Patients
This was a prospective first-in-human study in 9 patients. All patients included were 18 y or older, with locally advanced or metastatic disease and a life expectancy 3 mo or more. Only patients who had a positive 68 Ga-DOTATATE scan within the preceding 6 mo were enrolled. Patients who had received chemotherapy within 3 wk or radiotherapy within 4 wk and those with serious underlying medical illness or unable to tolerate scanning were excluded. Previous imaging was recorded to ascertain disease sites alongside histopathology, gut hormones, chromogranin levels (CgA and CgB), and Ki-67 index. The date and dose of the last octreotide/lanreotide injection were recorded where relevant. The Leeds East and Humberside Research Ethics Committee approved this study, and all subjects signed a written informed consent form. The study was conducted according to the Declaration of Helsinki. The administration of radioactivity was approved by the Administration of Radioactive Substances Advisory Committee, U.K. The Medicines and Health Care Products Regulatory Agency (U.K.) gave permission to administer the Investigational Medicinal Product (European Clinical Trials no. 2013-003152-20).
Safety
Safety data were obtained during and 24 h after radioligand administration. Data recorded included vital signs (heart rate, blood pressure, respiratory rate, and body temperature); physical examination; cardiovascular, lung, abdomen, and neurologic examinations; electrocardiogram; and laboratory parameters (serum biochemistry, hematology, coagulation, and urinalysis). Any adverse events were recorded using the common toxicity criteria (version 4.03; http://www.eortc.be/services/doc/ctc/ CTCAE_4.03_2010_0614_QuickReference_5 · 7.pdf).
Image Acquisition
Images were acquired on a Biograph 6 TruePoint PET/CT scanner (with TrueV; extended field of view [Siemens]) with 21.6-cm axial and 60.5-cm transaxial fields of view. An attenuation CT scan of each patient was obtained before administration of 18 F-FET-bAG-TOCA, from the vertex to the mid thigh (CT settings: tube potential, 130 kV; exposure, 15 effective mAs; pitch, 1.5; slice thickness, 5 mm; rotation time, 0.6 s; resulting in an effective dose of 2.5 mSv). This scan was then followed by a multibed whole-body PET scanning protocol on 6 occasions within a 4-h period. A break after the fourth emission scan allowed voiding to enhance radioligand clearance and was followed by a second CT and the last 2 multibed whole-body PET scans (Supplemental Table 1 ; supplemental materials are available at http://jnm.snmjournals.org).
All emission scans were reconstructed using the ordered-subsets expectation maximization algorithm (3 iterations and 21 subsets) with corrections for dead time, scatter, attenuation, and radioactive decay. Volumes of interest for as many of the possible International Commission on Radiological Protection (ICRP) 103 source organs were outlined (10), using the ANALYZE software package (version 11; Biomedical Imaging Resource, Mayo Clinic). All source organs were manually outlined on screen using a circular paint-brush of fixed diameter and width, by a single investigator to avoid any interobserver variation.
Blood Activity Measurements
Discrete venous bloods and plasma (at 5, 10, 15, 30, 60, 90, and 150 min after injection) were obtained for radioactivity counting and metabolite analysis, as previously described (8) .
Data Analysis, Biodistribution, and Dosimetry
The mean non-decay-corrected 18 F activity was obtained for the source organ regions of interest at each whole-body scan time, resulting in time-activity curves. The curves were decay-corrected to the midpoint of each whole-body scan to most closely represent the average activity distribution for the scan. To account for the activity remaining in the body at the end of the scan protocol, the time-activity curves were extrapolated from the last whole-body scan with the simplification that radioactive decay would be the only significant change. The curves were converted to activity per organ using the volume of organs in ICRP 23 reference man (11) and normalized by the injected activity to give the fractional uptake in each organ as a function of time. These timeactivity curves were trapezoidally integrated to generate organ residence times, the total number of disintegrations in each source organ per unit injected activity.
Bladder radioactivity, unlike other organs, was calculated, taking into account the bladder volume changes over the time course of the scan (12) (13) (14) (15) . The effective dose (ED) was calculated using, first, the mean residence time over all subjects for each organ and, second, residence times for individual subjects with OLINDA/ EXM (version 1.1), which uses the organ weighting factors from ICRP 60 (16) .
RESULTS
Patients
In this prospective study, 9 patients (6 women and 3 men) were recruited: 6 patients with gastroenteropancreatic NETs and 3 with lung NETs. One patient had known multiple endocrine neoplasia type 1 (MEN1) syndrome whereas the other tumors were sporadic. MEN1, an autosomal dominant hereditary syndrome for which patients develop pituitary, parathyroid, pancreatic, and adrenal tumors, is detected through familial screening. 68 Ga-DOTA peptides allow the detection of NET lesions in MEN1 syndrome patients and can be used as an additional tool to CT scanning. The mean age and weight 6 SD were 56 y 6 12.8 (range, 35-73 y) and 75.2 6 11.8 kg (range, 66.3-91.2 kg), respectively. Study schedule (Fig. 1B) , patient demographics, and clinical characteristics ( Table 1) were summarized. The median CgA and CgB levels, reflecting in part the burden of disease (17), were 95 (range, 24-1,567) and 170 pmol/L (range, 58-1,328), respectively. Tumor staging and grading were in accordance with the European Neuroendocrine Tumor Society consensus classification systems (18) . In our cohort of patients, 22% (2/9) were graded as G1 (#2) and 78% (7/9) were G2. Safety There were no adverse or clinically detectable pharmacologic events during the study or within 24 h after 18 F-FET-bAG-TOCA injection. No significant changes in vital signs or the results of laboratory studies or electrocardiograms were observed. Radiopharmaceutical 18 F-FET-bAG-TOCA formulated for injection was obtained from fluoride in 6.2% 6 2.9% non-decay-corrected radiochemical yield (range, 2.0%-12.1%) within 100 min. Radiochemical purity was 100%, and specific radioactivity was 374 6 124 GBq/mmol (range, 224-562 GBq/mmol). The mean (6SD) of the administered mass of 18 F-FET-bAG-TOCA was 0.86 6 0.26 mg (range, 0.52-1.32 mg). The mean administered activity was 155.7 6 8 MBq (range, 137-163 MBq).
Metabolite Analysis
The metabolism of 18 F-FET-bAG-TOCA was analyzed using radio-HPLC (1200 series system; Agilent). Typical high-performance liquid chromatograms for subject 1 are illustrated in Figure 2 . Over 60% of parent radioligand was detectable in plasma at 60 min, and over 30% of parent radioligand was detectable at 2.5 h (Supplemental Fig. 1 ). There was a rapid equilibration of radioactivity in blood, with a blood-to-plasma ratio of approximately 1.5. From the parent plasma data, the elimination half-lives of the distribution and terminal/elimination phase were calculated as 2.95 6 0.87 and 15.87 6 6.84 min, respectively (fit: R 2 range, 0.98-1.0), demonstrating rapid radioligand clearance from the blood compartment. The identity of the metabolites are presently unknown; no bone uptake was seen, thus precluding significant defluorination. 
MEN1.
RFA 5 radiofrequency ablation; SCF 5 supraclavicular fossa lymph node.
Image Quality
Images obtained with 18 F-FET-bAG-TOCA PET/CT showed excellent contrast (Fig. 3 ). The image of patient 1, diagnosed with a small bowel NET and widespread metastases (bone, liver), shows avid uptake of 18 F-FET-bAG-TOCA. Figure 4 shows images of a patient with known MEN1 syndrome and with lesions localized within the pancreas. Biodistribution 18 F-FET-bAG-TOCA-derived radioactivity was visually detectable in the vascular compartment, liver, spleen, and kidneys, within the first 6 min of radioligand injection. There were no significant differences in organ biodistribution between male and female patients ( Fig. 5) . Tissue time-activity curves generated for the main source organs are shown in Figure 6 . Over the next 192 min, increased radioligand localization was seen in the gallbladder, spleen, and bladder. Physiologic uptake was also noted in the pituitary, salivary glands, and thyroid. The radioligand also showed high tumor uptake ( Fig. 6C) and tumor-to-background contrast in all organs including the liver. Three lesions were chosen per patient where available, and in patients with multiple metastases, 3 lesions were chosen from different sites. In patients with multiple liver lesions only, 3 clearly visible lesions were identified and used for measurement of SUV.
The mean residence times in male and female patients are shown (Table 2 ). Overall, the radioligand was eliminated rapidly from most organs, leading to relatively short residence times and low/stable organ radioactivity within 60 min of radioligand injection. Bladder radioactivity was variable; an example of a bladder time-activity curve for subject 1 using the 3-parameter-fit model is illustrated in Supplemental Figure 2 .
Dosimetry
The calculated ED using mean organ residence times over all 9 subjects was 0.029 mSv/MBq. When using time-activity curves for individual subjects, the calculated ED ranged from 0.022 to 0.032 mSv, giving an SD of 0.004 mSv. The estimated mean absorbed dose to all source organs assuming a 2-h bladder voiding scenario in individual patients (1) (2) (3) or all patients combined is shown in Figure 7 . The organs that received the highest dose (mSv/MBq) in descending order were the gallbladder wall (0.149 6 0.007), spleen (0.117 6 0.036), stomach wall (0.076 6 0.02), liver (0.066 6 0.009), kidneys (0.065 6 0.011), and urinary bladder (0.051 6 0.015).
DISCUSSION
18 F-FET-bAG-TOCA, a SSTR-2 targeting 18 F radioligand, has been shown in this first-in-human study to be safe and well tolerated. Goodmanufacturing-practice-compliant 18 F-FET-bAG-TOCA was produced on an automated platform; synthesis time of 18 F-FET-bAG TOCA, using the click reaction (9) , was shown to be shorter than other 18 Foctreotate analogs and resulted in reasonable radioligand yields (19) . 18 F-FET-bAG-TOCA had acceptable metabolic stability with little or no defluorination. Intact parent radioligand was detectable in plasma by HPLC throughout the study; radioactivity in urine comprised up to 90% of parent radioligand at 90 min after injection (data not shown).
Future users of this radioligand should be cognizant of physiologic localization. Low-level physiologic localization was seen in the pituitary, salivary glands, thyroid, and spleen, and elimination via the gallbladder increased over time. Rapid distribution to the liver was noted, but over time there was gradual elimination of radioligand in this organ and background activity proved to be less than other previously described 18 F-octreotate-based radioligands (19, 20) . This is in keeping with preclinical studies in mice. 18 F-FET-bAG-TOCA was selected from a library of compounds mainly because of its low level of uptake in the liver-a common site for metastases in neuroendocrine tumors-while retaining reasonably high binding affinity comparable to ( 18 F-AIF-NOTA-OC) or higher than existing clinically applicable radioligands ( 68 Ga-DOTATATE) (8, 9) .
The main pharmacokinetic difference between 18 F-FET-bAG-TOCA and 68 Ga-emitting somatostatin radioligands relates to the highest absorbed dose received by source organs, in which, in descending order, the spleen, bladder, kidneys, and liver receive the highest dose with 68 Ga-emitting somatostatin radioligands. In comparison, for 18 F-FET-bAG-TOCA, the gallbladder received the highest absorbed dose. This is to be expected because 18 F-FET-bAG-TOCA had both renal and biliary elimination, whereas 68 Ga-based ligands have predominantly renal elimination (21) (22) (23) . In our cohort of patients with liver metastases, the tumor-to-background ratio for 18 F-FET-bAG-TOCA in the liver (4.23 6 2.69) was broadly similar to that reported for 68 Ga-DOTANOC (3.4 6 2.3), 68 Ga-DOTATOC (2.8 6 1.6), and 68 Ga-DOTATATE (2.0; interquartile range, 1.4-2.7) (24) (25) (26) .
The dosimetry of 18 F-FET-bAG-TOCA was similar to other 18 F-based radioligands. The mean ED was found to be 0.029 6 0.004 mSv/MBq, which is comparable to the ED of 18 F-FDG (0.019 mSv/MBq) (27) . Radiation safety of 18 F-FET-bAG-TOCA was inferred from the organ absorbed dose estimates obtained from our study; all values were within the limits suggested by the U.S. Food and Drug Administration Code of Federal regulation Title 21, part 361.1.
Although ours was a small cohort of patients, we observed no trend between SUVs and blood biomarkers or grade of tumors. Patient 1, for instance, was found to have a high tumor burden reflected by high chromogranin CgA and CgB levels and high SUV of lesions within the liver, bone, and bowel; however, patient 3 (lung NET) showed low tumor burden with low SUV, but CgA and CgB levels were high. Additionally, patient 7 (pancreatic NET) was found to have low levels of CgA despite having widespread liver metastases on 18 F-FET-bAG-TOCA PET/CT. This lack of correlation Ovaries could not be visualized in 1 subject because of postmenopausal atrophy, and 2 subjects had previous hysterectomy and bilateral salpingo-oophorectomy. ¶ Urinary bladder mean residence time is for 2-h voiding model. between imaging and biomarkers has also been highlighted in other studies (28, 29) and suggests that additional multianalyte biomarkers such as circulating NET gene transcripts should be considered in the future (30) .
The MEN1 syndrome-positive patient in our study had previous pituitary surgery and therefore showed no uptake within this region (physiologic or pathologic). Imaging with 18 F-FET-bAG-TOCA detected multiple NETs within the pancreas, and as expected there were no differences in SUVs of lesions between the MEN1-positive patient and other patients with gastroenteropancreatic NETs or lung NETs. 18 F-FET-bAG-TOCA has shown initial promise with its ease of synthesis, high production yield, and accessibility for large multicenter studies, and clinical studies in an expanded cohort, with a single static whole-body imaging protocol based on this study, are currently ongoing to clinically qualify the ligand in patients with NET, by direct comparison with 68 Ga-DOTATATE PET/CT. The potential of this SSTR-specific radioligand, with high specificity for SSTR-2, highlights the possibility for use both in diagnosis and in treatment planning, an attractive option in NET patients. This concept of theranostics (therapies that combine diagnostic and therapeutic capabilities into a single agent) in nuclear medicine has gained popularity and is one step forward in achieving a personalized medicine approach in NET patients. Although this concept applies directly to 68 Ga-DOTA radioligands (31) , it is envisaged that the 18 F variant can be used, indirectly, to personalize similar therapies.
CONCLUSION
We report a click 18 F-radiolabeled octreotate PET imaging radiopharmaceutical with appropriate safety, dosimetry, and distribution properties, which highlights tumor lesions with high contrast. With the range of treatment modalities available in the management of NETs, the use of an optimal imaging modality, together with blood biomarkers in the clinic, is of great importance in the therapeutic decision-making process of NET patients.
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